Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis

Inclusion criteria

Participants must meet all the following criteria to be eligible for inclusion in this study:

• Pulmonary fibrosis (PF) participants in Japan. Note: This includes those clinically recognized as having idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF).
• Participants who are ≥18 years of age at the time of providing informed consent via the web-based system.
• Participants receiving outpatient care for pulmonary fibrosis (PF) who have been introduced to this study by a referring physician.
• Participants who have a history of taking, or are currently taking, pirfenidone, nintedanib, or nerandomilast.
• Participants who have experienced at least one antifibrotic (AF) therapy-related adverse event (AE).

• Discontinuation group only

• Participants who have not received AF therapy for at least 1 month prior to enrollment.

• Participants whose AF therapy was discontinued within 6 months prior to enrollment.

• Participants whose reason for discontinuing AF therapy includes at least one AF therapy-related AE.

• Continuation group only

• Participants who feel or have felt burdened by the experienced AE.
• Participants who have continued AF therapy for a specific period (≥6 months) at the time of enrollment.

Exclusion criteria

Participants meeting any of the following criteria will be excluded from the study:

<!-- -->

• Participants currently participating in any interventional clinical trials (regardless of the study drug, excluding observational studies).
• Participants who have undergone lung transplantation.
• Discontinuation group only 1) Participants who discontinued AF therapy solely for reasons other than AE (e.g., financial reasons, disease progression).